ArriVent BioPharma (AVBP) Other Non-Current Assets (2023 - 2026)
ArriVent BioPharma (AVBP) posted Other Non-Current Assets of $156000.0 for Q1 2026, down 17.89% sequentially from $190000.0 in Q4 2025, and down 11.36% YoY from $176000.0 in Q1 2025.
ArriVent BioPharma (AVBP) Other Non-Current Assets (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Other Non-Current Assets for 4 years, with the latest figure at $156000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 11.36% year-over-year to $156000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156000.0 (down 11.36% YoY) and the FY2025 annual result came in at $190000.0, up 50.79% from the prior year.
- Other Non-Current Assets fell to $156000.0 in Q1 2026 per AVBP's latest filing, from $190000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $479000.0 in Q2 2025 and troughed at $107000.0 in Q4 2023.
- A 4-year average of $177300.0 and a median of $141000.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets surged 283.2% in 2025, then retreated 11.36% in 2026.
- Over 4 years, Other Non-Current Assets stood at $107000.0 in 2023, then climbed by 17.76% to $126000.0 in 2024, then soared by 50.79% to $190000.0 in 2025, then declined by 17.89% to $156000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $156000.0, $190000.0, and $180000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 134,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134,000.00 |
| Mar 31, 2026 | 156,000.00 |
| Dec 31, 2025 | 190,000.00 |
| Sep 30, 2025 | 180,000.00 |
| Jun 30, 2025 | 479,000.00 |
| Mar 31, 2025 | 176,000.00 |
| Dec 31, 2024 | 126,000.00 |
| Sep 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 125,000.00 |
| Mar 31, 2024 | 108,000.00 |
| Dec 31, 2023 | 107,000.00 |